TXNDC17: A Potential Drug Target and Biomarker (G84817)

Target Name: TXNDC17

NCBI ID: G84817

TXNDC17

TXNDC17: A Potential Drug Target and Biomarker

Thioredoxin-like 5 (TXNDC17) is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of cellular processes such as DNA replication, gene expression, and cell growth, and has been implicated in a number of diseases, including cancer. In recent years, researchers have been investigating the potential uses of TXNDC17 as a drug target and biomarker.

The TXNDC17 protein is composed of 254 amino acids and has a calculated molecular mass of 31.1 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and pancreas, and is involved in the regulation of DNA replication, gene expression, and cell growth. It has been shown to play a role in the development and progression of a number of diseases, including cancer.

One of the key functions of TXNDC17 is its role in the regulation of DNA replication. TXNDC17 has been shown to interact with the protein responsible for the enzyme DNA polymerase, which is essential for the replication of DNA in the cell. This interaction between TXNDC17 and DNA polymerase suggests that it may be a useful target for drugs that are designed to inhibit DNA replication in cancer cells.

In addition to its role in DNA replication, TXNDC17 is also involved in the regulation of gene expression. It has been shown to interact with the protein responsible for the transcription factor RNA polymerase II (RNA-P2), which is essential for the translation of DNA into RNA. This interaction between TXNDC17 and RNA-P2 suggests that it may be a useful target for drugs that are designed to inhibit gene expression in cancer cells.

The potential uses of TXNDC17 as a drug target are vast. In addition to its role in the regulation of DNA replication and gene expression, it is also involved in the regulation of cell growth and the development of cancer. It has been shown to play a role in the development of many types of cancer, including breast, ovarian, and prostate cancer. This suggests that TXNDC17 may be an effective target for cancer therapies that are designed to inhibit its activity.

In addition to its potential as a drug target, TXNDC17 is also a potential biomarker. Its expression has been shown to be altered in a variety of diseases, including cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these diseases. In addition, its regulation by DNA replication and gene expression makes it an attractive target for researchers who are studying the mechanisms of these processes in cancer.

In conclusion, TXNDC17 is a protein that is involved in a variety of cellular processes and has been implicated in a number of diseases, including cancer. Its interaction with DNA polymerase and RNA-P2 suggests that it may be a useful drug target and biomarker. Further research is needed to fully understand its potential uses and to develop effective therapies that can inhibit its activity.

Protein Name: Thioredoxin Domain Containing 17

Functions: Disulfide reductase. May participate in various redox reactions through the reversible oxidation of its active center dithiol to a disulfide and catalyze dithiol-disulfide exchange reactions. Modulates TNF-alpha signaling and NF-kappa-B activation. Has peroxidase activity and may contribute to the elimination of cellular hydrogen peroxide

The "TXNDC17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TXNDC17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets